Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Mexico - Delayed Quote MXN

bluebird bio, Inc. (BLUE.MX)

Compare

80.00

0.00

(0.00%)

As of March 3 at 1:43:52 PM CST. Market Open.

Gene therapy maker bluebird to go private in discounted deal amid cash crunch

(Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital Partners at a discount, after a prolonged struggle to survive a cash crunch due to a difficult market environment for gene therapies. The company first raised going concern doubts three years ago and laid off a quarter of its workforce last year to focus on launching its three gene therapies, including Lyfgenia for sickle cell disease, which has seen slow uptake, partly due to a lengthy treatment process. The go-private deal will now provide the "primary capital" required to scale bluebird's commercialization efforts for gene therapies.

Reuters 13 days ago

BLUE
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird pri

Business Wire 13 days ago

CG

BLUE
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat […]

Insider Monkey 2 months ago

BLUE
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass., December 08, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6

Business Wire 2 months ago

BLUE
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass., December 07, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

Business Wire 2 months ago

BLUE
bluebird bio Announces 1-for-20 Reverse Stock Split

SOMERVILLE, Mass., December 04, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock Split") of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the Company’s common s

Business Wire 2 months ago

BLUE
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

SOMERVILLE, Mass., December 04, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs).

Business Wire 2 months ago

BLUE
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio ( NASDAQ:BLUE ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.6m (down 14% from 3Q...

Simply Wall St. 3 months ago

BLUE
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.

Business Wire 3 months ago

BLUE
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

SOMERVILLE, Mass., November 06, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The

Business Wire 3 months ago

BLUE
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass., November 05, 2024--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition

Business Wire 3 months ago

BLUE
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical industry remains a hub of […]

Insider Monkey 4 months ago

BLUE
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a severe neurological disorder in clinical trials have developed blood cancers. This marks an increase of four cases since June 2022, when the emergence of three cancer cases led the FDA to convene an advisory panel before approving the therapy, now marketed as Skysona. The STAT News report noted that one child passed away due to complications from cancer treatment. Also Read:

Benzinga 4 months ago

BLUE
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and Skysona.

Pharmaceutical Technology 4 months ago

BLUE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOMERVILLE, Mass., October 04, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the previously disclosed 100,000 RSUs granted to the Company’s CFO, James Sterling, with a grant date of September 30, 2024 and 142,500 RSUs granted to 19 other employees, with a grant date of October 1, 2024 (collectively, the "Inducement Grants").

Business Wire 4 months ago

BLUE
Bluebird: Q2 Earnings Snapshot

SOMERVILLE, Mass. AP) — Bluebird Bio Inc. BLUE) on Friday reported a loss of $81.4 million in its second quarter.

Associated Press Finance 5 months ago

BLUE
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

SOMERVILLE, Mass., September 27, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") with the Securities and Exchange Commission ("SEC").

Business Wire 5 months ago

BLUE
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year

On Tuesday, Bluebird bio, Inc. (NASDAQ:BLUE) announced it is implementing a restructuring intended to optimize its cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the company’s workforce of approximately 25%. The company’s cash flow break-even target assumes scaling

Benzinga 5 months ago

BLUE
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

SOMERVILLE, Mass., September 24, 2024--Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduct

Business Wire 5 months ago

BLUE
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

SOMERVILLE, Mass., September 13, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), including the restated information, and Form 10-Q for the quarter ended March 31, 2024 (the "Q1 2024 Form 10-Q") with

Business Wire 5 months ago

BLUE

Performance Overview

Return	BLUE.MX	S&P 500
YTD	-57.21%	-2.27%
1-Year	-93.04%	+12.60%
3-Year	-96.58%	+32.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

bluebird bio, Inc. (BLUE.MX)

Gene therapy maker bluebird to go private in discounted deal amid cash crunch

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bluebird: Q2 Earnings Snapshot

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Performance Overview